Palbociclib (PD-0332991) HCl

Name: Palbociclib (PD-0332991) HCl
Brand: Selleck Chemicals
SKU: S1116
Rating: 5 (322 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1116

322 publications

Palbociclib (PD-0332991) HCl Chemical Structure

CAS No. 827022-32-2

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Selleck's Palbociclib (PD-0332991) HCl has been cited by 322 publications

Nat Med, 2021, 10.1038/s41591-020-01168-7

PubMed: 33462444 ( click the link to review the publication )

Cancer Cell, 2021, S1535-6108(21)00383-4

PubMed: 34388376 ( click the link to review the publication )

Nature, 2020, 17

PubMed: 32555459 ( click the link to review the publication )

Nature, 2020, 583(7817):620-624

PubMed: 32669709 ( click the link to review the publication )

Cell, 2020, 16;181(2):424-441.e21.

PubMed: 32234521 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Stem Cell, 2020, 27(1):50-63.e5

PubMed: 32619518 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):340-353

PubMed: 32109375 ( click the link to review the publication )

Cell, 2019, 176(5):1083-1097

PubMed: 30739799 ( click the link to review the publication )

Nat Med, 2019, 25(2):292-300

PubMed: 30664779 ( click the link to review the publication )

Cancer Discov, 2019, 10.1158/2159-8290.CD-18-0830

PubMed: 31594766 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2018, 553(7686):91-95

PubMed: 29160310 ( click the link to review the publication )

Cell, 2018, 174(5):1127-1142

PubMed: 30078706 ( click the link to review the publication )

Cancer Cell, 2018, 9;34(1):56-68.e9

PubMed: 29990501 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(2):277

PubMed: 29395057 ( click the link to review the publication )

Cancer Discov, 2017, 7(10):1168-1183

PubMed: 28801307 ( click the link to review the publication )

Nat Immunol, 2017, 18(3):293-302

PubMed: 28092373 ( click the link to review the publication )

Mol Cell, 2021, 81(19):4041-4058.e15

PubMed: 34624217 ( click the link to review the publication )

Genome Biol, 2021, 22(1):176

PubMed: 34108027 ( click the link to review the publication )

Nat Commun, 2021, 12(1):5386

PubMed: 34508104 ( click the link to review the publication )

Nat Commun, 2021, 12(1):3356

PubMed: 34099663 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkab805

PubMed: 34534348 ( click the link to review the publication )
Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-20-3458

PubMed: 34103301 ( click the link to review the publication )

J Cell Biol, 2021, 220(8)e202009147

PubMed: 34037657 ( click the link to review the publication )

Cell Rep, 2021, 36(4):109436

PubMed: 34320337 ( click the link to review the publication )

Cell Rep, 2021, 34(3):108636

PubMed: 33472061 ( click the link to review the publication )

Elife, 2021, 10e61797

PubMed: 33522487 ( click the link to review the publication )

Elife, 2021, 10e65234

PubMed: 33983115 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)E372

PubMed: 33498427 ( click the link to review the publication )

Cancers (Basel), 2021, 13(10)2396

PubMed: 34063457 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):54

PubMed: 33723248 ( click the link to review the publication )

Cells, 2021, 10(9)2391

PubMed: 34572040 ( click the link to review the publication )

FASEB J, 2021, 35(1):e21229

PubMed: 33368613 ( click the link to review the publication )

Cancer Discov, 2021, candisc.1114.2020

PubMed: 33879449 ( click the link to review the publication )

Mol Cancer Ther, 2021, 10.1158/1535-7163.MCT-20-0848

PubMed: 34158347 ( click the link to review the publication )

Mol Cancer Ther, 2021, 10.1158/1535-7163.MCT-20-1126

PubMed: 34376578 ( click the link to review the publication )

Neoplasia, 2021, 23(1):140-148

PubMed: 33316538 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2021, 1868(7):119044

PubMed: 33865884 ( click the link to review the publication )

Mol Cancer Res, 2021, 19(6):1026-1039

PubMed: 33627502 ( click the link to review the publication )

Mol Cancer Res, 2021, 19(4):651-666

PubMed: 33443106 ( click the link to review the publication )

Cancer Biol Med, 2021, 18(1):227-244

PubMed: 33628597 ( click the link to review the publication )

Front Oncol, 2021, 11:681530

PubMed: 34277427 ( click the link to review the publication )

Front Oncol, 2021, 11:696713

PubMed: 34395263 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(9)4559

PubMed: 33925399 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(6)2915

PubMed: 33805656 ( click the link to review the publication )

Sci Rep, 2021, 11(1):14736

PubMed: 34282211 ( click the link to review the publication )
Sci Rep, 2021, 11(1):7259

PubMed: 33790333 ( click the link to review the publication )

Cancer Gene Ther, 2021, 10.1038/s41417-021-00375-9

PubMed: 34385584 ( click the link to review the publication )

Breast Cancer Res Treat, 2021, 186(3):677-686

PubMed: 33599863 ( click the link to review the publication )

Clin Genitourin Cancer, 2021, S1558-7673(21)00029-X

PubMed: 33676835 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

J Pers Med, 2021, 11(4)292

PubMed: 33921303 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)524

PubMed: 33572972 ( click the link to review the publication )

Breast Cancer Res, 2021, 23(1):26

PubMed: 33602273 ( click the link to review the publication )

Anal Chem, 2021, 93(5):3052-3060

PubMed: 33502178 ( click the link to review the publication )

Cell Rep, 2021, 34(7):108744

PubMed: 33596421 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

J Clin Invest, 2020, 134132

PubMed: 33016930 ( click the link to review the publication )

Nat Commun, 2020, 11(1):71

PubMed: 31900415 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5305

PubMed: 33082317 ( click the link to review the publication )

Nat Commun, 2020, 2;11(1):2760

PubMed: 32488085 ( click the link to review the publication )

Nat Commun, 2020, 11(1):385

PubMed: 31959756 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

EMBO J, 2020, 2;e104036

PubMed: 32484965 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Dev Cell, 2020, 55(6):707-722.e9

PubMed: 33321102 ( click the link to review the publication )

Leukemia, 2020, 10.1038/s41375-020-0943-5

PubMed: 32591645 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2706

PubMed: 32086342 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

J Cell Biol, 2020, 1;219(6)

PubMed: 32236513 ( click the link to review the publication )
J Cell Biol, 2020, 2;219(3)

PubMed: 32211891 ( click the link to review the publication )

Cancer Res, 2020, 80(16):3215-3221

PubMed: 32606000 ( click the link to review the publication )

Cancer Res, 2020, 80(18):3841-3854

PubMed: 32690724 ( click the link to review the publication )

Cell Rep, 2020, 33(9):108449

PubMed: 33264622 ( click the link to review the publication )

Cell Rep, 2020, 32(10):108102

PubMed: 32905768 ( click the link to review the publication )

Elife, 2020, 7;9:e44571

PubMed: 32255427 ( click the link to review the publication )

Haematologica, 2020, haematol.2020.249177

PubMed: 32855276 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):262

PubMed: 33243298 ( click the link to review the publication )

Cancers (Basel), 2020, 6;12(4)

PubMed: 32268485 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32197329 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):87

PubMed: 32787886 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):754

PubMed: 32934219 ( click the link to review the publication )

Cells, 2020, 26;9(4)

PubMed: 32225025 ( click the link to review the publication )

Cancer Discov, 2020, 13;CD-19-1390

PubMed: 32404308 ( click the link to review the publication )

Cancer Discov, 2020, 4;CD-20-0329

PubMed: 32499221 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(10):2221-2232

PubMed: 32747423 ( click the link to review the publication )

Front Oncol, 2020, 10:563249

PubMed: 33072590 ( click the link to review the publication )

J Cell Sci, 2020, 133(18)jcs247940

PubMed: 32878943 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(9)E3214

PubMed: 32370101 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32708306 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32046095 ( click the link to review the publication )

Sci Rep, 2020, 10(1):18489

PubMed: 33116269 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:280

PubMed: 32624705 ( click the link to review the publication )
Cancer Cell Int, 2020, 20:501

PubMed: 33061853 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):941

PubMed: 32998722 ( click the link to review the publication )

Open Biol, 2020, 10(10):200200

PubMed: 33052073 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Breast Cancer, 2020, 10.1007/s12282-020-01090-3

PubMed: 32297248 ( click the link to review the publication )

Nat Struct Mol Biol, 2020, 27(1):92-104

PubMed: 31925410 ( click the link to review the publication )

Nature, 2020, 583(7817):620-624

PubMed: 32669709 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):89

PubMed: 32795346 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0236298

PubMed: 32701996 ( click the link to review the publication )

bioRxiv, 2020, 10.1101/2020.11.26.400499

PubMed: None ( click the link to review the publication )

Sci Rep, 2020, 10(1):11574

PubMed: 32665693 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01403-y

PubMed: 32712628 ( click the link to review the publication )

J Pathol, 2020, e5493

PubMed: 32558936 ( click the link to review the publication )

Cancer Cell, 2020, 38(1):44-59.e9

PubMed: 32663469 ( click the link to review the publication )

Clin Transl Med, 2020, 10(1):182-198

PubMed: 32508030 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa653

PubMed: 32761127 ( click the link to review the publication )

Anticancer Res, 2020, 40(12):6699-6712

PubMed: 33288563 ( click the link to review the publication )

Gut, 2019, 68(2):207-217

PubMed: 29703791 ( click the link to review the publication )

Nat Microbiol, 2019, 4(12):2260-2272

PubMed: 31548682 ( click the link to review the publication )

Mol Cell, 2019, 76(4):562-573

PubMed: 31543423 ( click the link to review the publication )

Mol Cell, 2019, 73(1):22-35.e6

PubMed: 30527665 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1373

PubMed: 30914635 ( click the link to review the publication )
Nat Commun, 2019, 10(1):557

PubMed: 30718506 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e11031

PubMed: 31512803 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2769

PubMed: 30692100 ( click the link to review the publication )

PLoS Biol, 2019, 17(3):e3000178

PubMed: 30865623 ( click the link to review the publication )

PLoS Biol, 2019, 17(8):e3000203

PubMed: 31430272 ( click the link to review the publication )

PLoS Biol, 2019, 17(4):e3000228

PubMed: 31039152 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2466-2479

PubMed: 30940663 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(7):2290-2304

PubMed: 30538111 ( click the link to review the publication )

Cell Rep, 2019, 26(10):2667-2680

PubMed: 30840889 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.119.232603

PubMed: 31481582 ( click the link to review the publication )

Oncogene, 2019, 38(25):4962-4976

PubMed: 30833638 ( click the link to review the publication )

Oncogene, 2019, 38(20):3886-3902

PubMed: 30692638 ( click the link to review the publication )

Sci Signal, 2019, 12(601):eaay0482

PubMed: 31575731 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)

PubMed: 31100952 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):271

PubMed: 30894510 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):376

PubMed: 31092814 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cells, 2019, 8(10)

PubMed: 31590445 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(2):300-306

PubMed: 30595531 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):771-779

PubMed: 30837298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0162

PubMed: 31395685 ( click the link to review the publication )
Mol Oncol, 2019, 13(8):1778-1794

PubMed: 31180176 ( click the link to review the publication )

Mol Neurobiol, 2019, 56(1):465-489

PubMed: 29721855 ( click the link to review the publication )

Oncogenesis, 2019, 8(7):38

PubMed: 31209198 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 163:133-141

PubMed: 30772267 ( click the link to review the publication )

J Transl Med, 2019, 17(1):245

PubMed: 31358010 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13405

PubMed: 31527634 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13696

PubMed: 31548560 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2019, 316(1):E135-E144

PubMed: 30512986 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(4):419-429

PubMed: 31467029 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.29249

PubMed: 31264276 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1685289

PubMed: 31747859 ( click the link to review the publication )

Exp Cell Res, 2019, 10.1016/j.yexcr.2019.111782

PubMed: 31857114 ( click the link to review the publication )

Am J Transl Res, 2019, 11(6):3481-3489

PubMed: 31312360 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

PLoS ONE, 2019,

PubMed: 31891587 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223555

PubMed: 31600301 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(4):967-973

PubMed: 31005255 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:11107-11117

PubMed: 31908479 ( click the link to review the publication )

Leuk Res, 2019, 78:3-11

PubMed: 30641417 ( click the link to review the publication )

Oncol Lett, 2019, 17(1):1153-1159

PubMed: 30655877 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 5:22

PubMed: 31372497 ( click the link to review the publication )
Nucleic Acids Res, 2019, 47(8):3921-3936

PubMed: 30805632 ( click the link to review the publication )

NPJ Precis Oncol, 2019, 03:18

PubMed: 31341951 ( click the link to review the publication )

Haematologica, 2019, 104(2):347-359

PubMed: 30262555 ( click the link to review the publication )

Oncotarget, 2019, 10(47):4907-4918

PubMed: 31448056 ( click the link to review the publication )

Eur J Med Chem, 2019, 165:115-132

PubMed: 30665142 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31399419 ( click the link to review the publication )

Gut, 2018, 10.1136/gutjnl-2017-314544

PubMed: 29884612 ( click the link to review the publication )

Mol Cell, 2018, 71(2):332-342

PubMed: 30017584 ( click the link to review the publication )

Mol Cell, 2018, 71(4):592-605

PubMed: 30057199 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(12):6188-6205

PubMed: 29873780 ( click the link to review the publication )

Autophagy, 2018, 14(4):637-653

PubMed: 29368982 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3994-4005

PubMed: 29716919 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-3094

PubMed: 30538112 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4360-4369

PubMed: 29844123 ( click the link to review the publication )

Cell Rep, 2018, 24(6):1597-1609

PubMed: 30089269 ( click the link to review the publication )

Cell Rep, 2018, 24(5):1105-1112.e5

PubMed: 30067968 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):112

PubMed: 30180865 ( click the link to review the publication )

Oncogene, 2018, 37(13):1685-1698

PubMed: 29335521 ( click the link to review the publication )

Oncogene, 2018, 37(37):5066-5078

PubMed: 29789718 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):446

PubMed: 29670090 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):897-907

PubMed: 29483214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )
Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )

Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582

PubMed: 29452249 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cell Signal, 2018, 44:1-9

PubMed: 29284139 ( click the link to review the publication )

J Orthop Res, 2018, 36(6):1581-1589

PubMed: 29194728 ( click the link to review the publication )

Cell Cycle, 2018, 17(11):1329-1344

PubMed: 30037299 ( click the link to review the publication )

Cell Cycle, 2018, 17(14):1784-1796

PubMed: 29995568 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0206368

PubMed: 30383785 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):424-430

PubMed: 29477843 ( click the link to review the publication )

SSRN, 2018, 10.2139/ssrn.3188455

PubMed: None ( click the link to review the publication )

Oncotarget, 2018, 9(79):34990-34995

PubMed: 30405888 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 102(5):1569-1576

PubMed: 30056081 ( click the link to review the publication )

Oncotarget, 2018, 9(77):34567-34581

PubMed: 30349650 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2018, 21(5):375-382

PubMed: 29764587 ( click the link to review the publication )

Oncotarget, 2018, 9(102):37753-37765

PubMed: 30701029 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Cell, 2018, 10.1016/j.cell.2018.11.011

PubMed: 30580964 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1061-1070

PubMed: 28759028 ( click the link to review the publication )

Sci Transl Med, 2017, 9(402)eaai7993

PubMed: 28794284 ( click the link to review the publication )

Mol Cell, 2017, 68(6):1134-1146

PubMed: 29225033 ( click the link to review the publication )

Nat Commun, 2017, 8(1):607

PubMed: 28928360 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1193

PubMed: 29084956 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1995

PubMed: 29222471 ( click the link to review the publication )
Nat Commun, 2017, 8(1):241

PubMed: 28808226 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(10):1415-1433

PubMed: 28778953 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(22):6958-6968

PubMed: 28814434 ( click the link to review the publication )

Dev Cell, 2017, 43(4):449-462

PubMed: 29103955 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.26957

PubMed: 29889021 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):123

PubMed: 28629371 ( click the link to review the publication )

Oncogene, 2017, 36(16):2255-2264

PubMed: 27748766 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(15):2427-2443

PubMed: 28444744 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

J Mol Cell Biol, 2017, 1;9(2):154-165

PubMed: 27927748 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1942-1953

PubMed: 28566433 ( click the link to review the publication )

Cell Oncol (Dordr), 2017, 40(3):209-218

PubMed: 28243976 ( click the link to review the publication )

Oncogenesis, 2017,

PubMed: 28504693 ( click the link to review the publication )

Sci Rep, 2017, 7(1):1535

PubMed: 28484242 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

PLoS One, 2017, 12(8):e0181601

PubMed: 28806746 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(3):676-688

PubMed: 27338091 ( click the link to review the publication )

Protein Sci, 2017, 26(4):870-879

PubMed: 28168755 ( click the link to review the publication )

Oncotarget, 2017, 8(48):83432-83445

PubMed: 29137354 ( click the link to review the publication )

JCO Precis Oncol, 2017, 1PO.17.00140

PubMed: 32913968 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(56):95116-95134

PubMed: 29221116 ( click the link to review the publication )
Oncotarget, 2017, 8(49):84743-84760

PubMed: 29156680 ( click the link to review the publication )

Oncotarget, 2017, 8(34):55848-55862

PubMed: 28915557 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(4):489-501

PubMed: 28965767 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47239-47249

PubMed: 28525384 ( click the link to review the publication )

Oncotarget, 2017, 8(33):55319-55331

PubMed: 28903422 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:11581

PubMed: 27181366 ( click the link to review the publication )

Nat Commun, 2016, 7:12748

PubMed: 27599659 ( click the link to review the publication )

Nat Commun, 2016, 7:11302

PubMed: 27066737 ( click the link to review the publication )

Nat Commun, 2016, 7:11987

PubMed: 27329820 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(1):122-33

PubMed: 26728409 ( click the link to review the publication )

EMBO Rep, 2016, 17(3):414-27

PubMed: 26882548 ( click the link to review the publication )

Leukemia, 2016, 30(1):86-93

PubMed: 26174628 ( click the link to review the publication )

Cell Death Differ, 2016, 23(3):430-41

PubMed: 26292757 ( click the link to review the publication )

Cell Mol Life Sci, 2016, 73(4):883-900

PubMed: 26346493 ( click the link to review the publication )

PLoS Pathog, 2016, 12(8):e1005829

PubMed: 27541004 ( click the link to review the publication )

Cell Death Dis, 2016, 7(10):e2419

PubMed: 27735950 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2486-2497

PubMed: 27507850 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(10):3203-3219

PubMed: 27486199 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3535-3551

PubMed: 28077803 ( click the link to review the publication )

J Cancer, 2016, 7(8):947-56

PubMed: 27313785 ( click the link to review the publication )

J Immunol, 2016, 197(7):2673-85

PubMed: 27566829 ( click the link to review the publication )

Sci Rep, 2016, 6:20376

PubMed: 26847534 ( click the link to review the publication )
Am J Physiol Cell Physiol, 2016, 310(7):C520-41

PubMed: 26718628 ( click the link to review the publication )

Oncotarget, 2016, 7(26):39595-39608

PubMed: 27167191 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84951-84964

PubMed: 27825114 ( click the link to review the publication )

Sci Rep, 2016, 6:19261

PubMed: 26763933 ( click the link to review the publication )

BMC Syst Biol, 2016, 10(1):73

PubMed: 27515956 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51163-51173

PubMed: 27323399 ( click the link to review the publication )

Oncotarget, 2016, 7(43):69111-69123

PubMed: 27564114 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Blood, 2015, 126(11):1324-35

PubMed: 26153519 ( click the link to review the publication )

Blood, 2015, 24;126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

J Natl Cancer Inst, 2015, 108(6):djv406

PubMed: 26719346 ( click the link to review the publication )

J Cell Biol, 2015, 210(7):1257-68

PubMed: 26416968 ( click the link to review the publication )

Sci Rep, 2015, 5:14391

PubMed: 26399741 ( click the link to review the publication )

J Biol Chem, 2015, 290(23):14462-75

PubMed: 25903125 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:76

PubMed: 26225123 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(9):1506-22

PubMed: 25733683 ( click the link to review the publication )

Cancer Med, 2015, 4(9):1417-25

PubMed: 26129688 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0140243

PubMed: 26460486 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143685

PubMed: 26606677 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

J Exp Med, 2015, 212(6):953-70

PubMed: 26008897 ( click the link to review the publication )

Oncotarget, 2015, 6(2):696-714

PubMed: 25557169 ( click the link to review the publication )

Oncotarget, 2015, 6(33):34629-48

PubMed: 26431489 ( click the link to review the publication )

Data Brief, 2015, 5:429-33

PubMed: 26958605 ( click the link to review the publication )
Oncotarget, 2015, 6(29):28057-70

PubMed: 26356814 ( click the link to review the publication )

Blood, 2014, 3;124(1):13-23

PubMed: 24764564 ( click the link to review the publication )

Cancer Res, 2014, 74(6):1739-51

PubMed: 24473065 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):662-74

PubMed: 24362465 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

AIDS, 2014, 28(15):2213-22

PubMed: 25036183 ( click the link to review the publication )

J Immunol, 2014, 193(4):1988-97

PubMed: 25015816 ( click the link to review the publication )

FEBS J, 2014, 281(18):4179-94

PubMed: 24823279 ( click the link to review the publication )

BMC Cancer, 2014, 14:32

PubMed: 24444383 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277205 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Universidade de Lisboa, 2014, Matias

PubMed: ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Cell Death Differ, 2013, 20(9):1241-9

PubMed: 23852369 ( click the link to review the publication )

Int J Cancer, 2013, 133(10):2341-50

PubMed: 23640782 ( click the link to review the publication )

PLoS Genet, 2013, 9(5):e1003546

PubMed: 23737759 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2722-34

PubMed: 24107447 ( click the link to review the publication )

J Virol, 2013, 87(8):4623-41

PubMed: 23408614 ( click the link to review the publication )

Pharmacogenomics J, 2013, 13(1):94-104

PubMed: 22083351 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cell Cycle, 2013, 12(15):2384-94

PubMed: 23839043 ( click the link to review the publication )

Cell Cycle, 2013, 12(23):3689-701

PubMed: 24189531 ( click the link to review the publication )
PLoS One, 2013, 8(11):e78641

PubMed: 24265703 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(17):4612-20

PubMed: 22761470 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2012, 26(2):236-46

PubMed: 23279822 ( click the link to review the publication )

Am J Cancer Res, 2012, 2(6):726-35

PubMed: 23226618 ( click the link to review the publication )

Cancer Prev Res (Phila), 2012, 5(6):810-21

PubMed: 22508966 ( click the link to review the publication )

Cell Cycle, 2012, 11(19):3599-610

PubMed: 22935696 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51847

PubMed: 23300567 ( click the link to review the publication )

georgetown university, 2012, georgetown university

PubMed: ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(20):8414-9

PubMed: 21536883 ( click the link to review the publication )

Clin Cancer Res, 2011, 1;17(13):4513-22

PubMed: 21593195 ( click the link to review the publication )

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

Features

Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Targets

CDK4/CyclinD3 ^[1] (Cell-free assay)	CDK4/CyclinD1 ^[1] (Cell-free assay)	CDK6/CyclinD2 ^[1] (Cell-free assay)
9 nM	11 nM	15 nM

In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser⁷⁸⁰. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. ^[1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. ^[2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. ^[3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MOLM13	MVfLbY5ie2ViQYPzZZk>		Moi0NlQhcA>?		M4DiXmlvcGmkaYTpc44hd2ZiQ1TLOEBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHJjKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFIh\|ryP	NGH6SI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[0NVExOyd-MkS2OFEyODN:L3G+
COLO205	M4HFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlW4O\|IhcA>?		MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODN4IN88US=>	M2O3ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSxNVA{Lz5{NE[0NVExOzxxYU6=
U937	NXXY[VdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUf2U3AzPzJiaB?=		NWXUfFl2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkG0JO69VQ>?	NUXvSYZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OFEyODNpPkK0OlQyOTB\|PD;hQi=>
MOLM13	M{PzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWL2VZlkPzJiaB?=		NV\NTZZISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTNiY3XscJMhcGG{Yn;ybY5oKE[OVEOgTXRFKG23dHHueEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt\|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>?	Mlr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NEGxNFMoRjJ2NkSxNVA{RC:jPh?=
MOLM13	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmrsO\|IhcA>?		MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO	MojlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NEGxNFMoRjJ2NkSxNVA{RC:jPh?=
MDA-MB-435	MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFfkZ4YzPCCq		M3zNRWlEPTB;MD6xOkDPxE1?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPThyMUizNUc,OTV6MEG4N\|E9N2F-
K562	NXrCOFFYS3m2b4TvfIlkKEG\|c3H5		MliwPVYhcA>?	NGrBNZhFVVOR	M4fEb2lEPTB;MjFOwG0>	NUL4eVlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVc2PjZpPkK0OFE4PTZ4PD;hQi=>
DU145	NGfaO2ZEgXSxdH;4bYMhSXO\|YYm=		MXW5OkBp	M4DTZ2ROW09?	NHfZfWRKSzVyPUeuOUDPxE1?	NVy1[3FbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVc2PjZpPkK0OFE4PTZ4PD;hQi=>
MDA-MB-231	NUTTV5NMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3NZXoyKM7:TR?=	M{PiU\|I1KGh?	MnLOSG1UVw>?	NX3aVlRFS2WubDDjfYNt\SCjcoLld5Qh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm	NGr3VIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxO\|U3Pid-MkS0NVc2PjZ:L3G+
MCF7	NHXhSHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXhNUDPxE1?	M2\TVlI1KGh?	M3\Fe2ROW09?	MV7D[YxtKGO7Y3zlJIFzemW\|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS\|EheGijc3W=	Mn7ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUe1OlYoRjJ2NEG3OVY3RC:jPh?=
MCF7	MVHLbY5ie2ViQYPzZZk>	M{X2TlUh\|ryP	NV7CS4lVOjRiaB?=	NIC5fopFVVOR	M2X5N2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC=	NVnuSIRyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVc2PjZpPkK0OFE4PTZ4PD;hQi=>
MDA-MB-231	NWPsTZo2U2mwYYPlJGF{e2G7	M{LuWFUh\|ryP	M3SwW\|I1KGh?	NV72d3B{TE2VTx?=	NUPSfndNUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzN{W2Okc,OjR2MUe1OlY9N2F-
MDA-MB-231	MVrGeY5kfGmxbjDBd5NigQ>?	MVWxMVExKM7:TR?=	Mmr1NlQhcA>?	NH\ubFZFVVOR	MY\kc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V?	NX;HbVd[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVc2PjZpPkK0OFE4PTZ4PD;hQi=>
MCF7	MUPGeY5kfGmxbjDBd5NigQ>?	NIDvTmMyNTFyIN88US=>	MmLUNlQhcA>?	Mn;6SG1UVw>?	NIDzUo9ld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W\|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W=	MlzUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUe1OlYoRjJ2NEG3OVY3RC:jPh?=
MDA-MB-231	MX7GeY5kfGmxbjDBd5NigQ>?	NYXyXYpGOC53LUGg{txO	NG\qNpU1QCCq	MXPEUXNQ	MlXabIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzN{W2Okc,OjR2MUe1OlY9N2F-
MCF7	MkPRSpVv[3Srb36gRZN{[Xl?	M4DHTlAvPS1zIN88US=>	NYO1blZtPDhiaB?=	NXjqVmRFTE2VTx?=	NInjR5Np[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO\|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>?	M4PNfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEG3OVY3Lz5{NESxO\|U3PjxxYU6=
MOLM13	NFHlV4tETEt2IHnubIljcXSrb36gZZN{[Xl?		NIi1PXozPCCq		MWHJR\|UxKD1iMD6wNVEh\|ryP	NVjCfVBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OFEyODNpPkK0OlQyOTB\|PD;hQi=>
A2780	M4TpfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkPEO\|IhcA>?		MkHzS2k2OCB;IECuNFMzKM7:TR?=	NU\rZoRrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixOVYyOTFpPkK4NVU3OTFzPD;hQi=>
COLO205	NEPqVWtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NVPNcpp2PzJiaB?=		MYrJR\|UxKD1iMD6wN\|Yh\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ2MUGwN{c,OjR4NEGxNFM9N2F-
MV4-11	NXX1NmRTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVG3NkBp		NF\PPGVIUTVyIE2gNE4xPSEQvF2=	M4fpdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUW2NVEyLz5{OEG1OlEyOTxxYU6=
MOLM13	NUjjbok6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFHaflc4OiCq		Mk\uS2k2OCB;IECuNFYzKM7:TR?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF3NkGxNUc,OjhzNU[xNVE9N2F-
NB4	MkHGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWnDfGlJPzJiaB?=		MorvS2k2OCB;IECuNFY3KM7:TR?=	Mn;EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNU[xNVEoRjJ6MUW2NVEyRC:jPh?=
PC3	NF3ZO4VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmiyO\|IhcA>?		MWDHTVUxKD1iMD6wO\|Eh\|ryP	M1rlWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUW2NVEyLz5{OEG1OlEyOTxxYU6=
MOLM13	MojvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MkPTO\|IhcA>?		NGLo[oFKSzVyIE2gNE4xQTZizszN	NVPwSWt4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OFEyODNpPkK0OlQyOTB\|PD;hQi=>
MOLM13	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MoC1O\|IhcA>?		MlfVTWM2OCB;IECuNFk3KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ2MUGwN{c,OjR4NEGxNFM9N2F-
MDA-MB-453	NHrwVGNEgXSxdH;4bYNqfHliYYPzZZk>		M{HGW\|Q5KGh?		NGLGOIFKSzVyIE2gNE4yOzdizszN	NF24NG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{S0PFkyOyd-Mke0OFg6OTN:L3G+
U937	M{TOdGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NGPyU4s4OiCq		NWXzfY91UUN3MDC9JFAvOTRizszN	NEHFOWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[0NVExOyd-MkS2OFEyODN:L3G+
MDA-MB-435	NIezbVhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MUCyOEBp		NV:2NFBQUUN3MDC9JFAvOTZizszN	NETR[4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxOVU4OSd-Mk[xNVU2PzF:L3G+
MCF7	M3vhVWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NUDOVpBWPDhiaB?=		NWfVO4I3UUN3MDC9JFAvOjRizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR2OEmxN{c,Ojd2NEi5NVM9N2F-
MDA-MB-453	NFn4e\|RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXy3NkBp		MnvNS2k2OCB;IECuN\|I3KM7:TR?=	MoHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNU[xNVEoRjJ6MUW2NVEyRC:jPh?=
MCF7	NV\IVVlyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUC3NkBp		MWHHTVUxKD1iMD61OVch\|ryP	M3XT[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUW2NVEyLz5{OEG1OlEyOTxxYU6=
MDA-MB-231	NHjlSWFEgXSxdH;4bYNqfHliYYPzZZk>		NYHCOHFpPDhiaB?=		MnPlTWM2OCB;IECuOVgh\|ryP	M4DGNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NES4PVE{Lz5{N{S0PFkyOzxxYU6=
M229	NGTUPIhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVi3NkBp		MoP6S2k2OCB;IEGuNlIh\|ryP	MnjyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNU[xNVEoRjJ6MUW2NVEyRC:jPh?=
M238	MmLkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MofyO\|IhcA>?		M3vsOGdKPTBiPTCxMlk4KM7:TR?=	M2fNWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUW2NVEyLz5{OEG1OlEyOTxxYU6=
M249	NYHBNnM4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NITaWXI4OiCq		MXPHTVUxKD1iMT65PUDPxE1?	MmHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNU[xNVEoRjJ6MUW2NVEyRC:jPh?=
K562	NXXOO\|NxS3m2b4TvfIlkcXS7IHHzd4F6		NIHybmc6PiCq		M1jQcWlEPTBiPTCyJO69VQ>?	M2DicVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEG3OVY3Lz5{NESxO\|U3PjxxYU6=
M249R	NVm1emxkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVm3NkBp		NELvXVlIUTVyIE2gNk46PiEQvF2=	MorVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNU[xNVEoRjJ6MUW2NVEyRC:jPh?=
MOLM13	M4LjSmZNXDNiaX7obYJqfGmxbjDhd5NigQ>?		MYSyOEBp		NY[0N5hXUUN3MDC9JFMh\|ryP	NV;aVWJ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OFEyODNpPkK0OlQyOTB\|PD;hQi=>
MDA-MB-468	M4GzVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MoHoNlQhcA>?		NFHpU45KSzVyIE2gN{DPxE1?	NVn2WnhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVU2PzFpPkK2NVE2PTdzPD;hQi=>
C4-2B	NILZ[\|dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYL1bIJPPzJiaB?=		MV;HTVUxKD1iND6xOUDPxE1?	MlvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNU[xNVEoRjJ6MUW2NVEyRC:jPh?=
DU145	M1Lydmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4nxd\|czKGh?		NX70ZoFpT0l3MDC9JFUvPzl{IN88US=>	MlqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNU[xNVEoRjJ6MUW2NVEyRC:jPh?=
MDA-MB-468	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NE\rPZg4OiCq		NHPSc4ZIUTVyIE2gOU46PiEQvF2=	NIK5dIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG1OlEyOSd-MkixOVYyOTF:L3G+
BPH1	M3rvW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXXmS5FCPzJiaB?=		MX7HTVUxKD1iNz60OFIh\|ryP	NXL4eFV6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixOVYyOTFpPkK4NVU3OTFzPD;hQi=>
DU145	NFW1UWJEgXSxdH;4bYNqfHliYYPzZZk>		NHfsbmQ6PiCq		MlXCTWM2OCB;IEeuOUDPxE1?	MonIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUe1OlYoRjJ2NEG3OVY3RC:jPh?=
MRC5	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{\LfFczKGh?		NFjxNJpIUTVyIE2gNVAh\|ryP	MnzUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNU[xNVEoRjJ6MUW2NVEyRC:jPh?=
697	M4PoWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PHeWlEPTB;MUS4MlM5KG6P	NHPJT4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
P12-ICHIKAWA	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF:ydIxKSzVyPUm2MlA1KG6P	Mn25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NB69	NEXlUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\hTWM2OD1zNkGuPEBvVQ>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
EoL-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7aTWM2OD1zOEeuNlYhdk1?	NFP1[VY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
BHT-101	MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXvV4IzUUN3ME2xPVgvOjVibl2=	NH21dVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SK-NEP-1	NFHx[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HGRmlEPTB;MkKwMlAzKG6P	Ml7MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
MHH-NB-11	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;pTWM2OD1{MkCuNVkhdk1?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
AsPC-1	NH7TPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUmzZodTUUN3ME2yOVIvPTNibl2=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
ES1	NGLwcYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7oTWM2OD1{NU[uNlUhdk1?	MkXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
LAMA-84	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFT6d2tKSzVyPUK1PE4yQSCwTR?=	NGG4OYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
MOLT-16	NXe0cYtVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fXPWlEPTB;MkW4MlQ6KG6P	MkHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
ES7	MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfpbpJJUUN3ME2yO\|MvODlibl2=	NULMUnBHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KY821	NH3vZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7rWXhiUUN3ME2zNVQvOSCwTR?=	MmXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
RT-112	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfqPYZKSzVyPUOyNU4xPSCwTR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HL-60	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\UOmlEPTB;M{SwMlY3KG6P	NYPEbpEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MOLT-4	NW\QNIdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTN2NT6xN{BvVQ>?	M{exfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
KARPAS-45	MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTN5Nj6xOkBvVQ>?	NVrESIlxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SK-N-AS	NI[1dplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmraTWM2OD1\|OEeuPFMhdk1?	NWjlWXB{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
CTB-1	NVSy[ndqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrCTWM2OD12MEWuNFIhdk1?	NWHxWJFHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NKM-1	NWPGbJM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnM[XlPUUN3ME20NVEvQDlibl2=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HTC-C3	NYP5TlJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTuTWM2OD12M{KuPVUhdk1?	MoHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
BE-13	M{XBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELWblFKSzVyPUS0OE4zPyCwTR?=	NGPHbog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
KOSC-2	NWjLW\|hWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTR4Nj65JI5O	NGjFd2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NB14	NFTIPXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETBZWpKSzVyPUS4N{42QCCwTR?=	MmnHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
CAL-27	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TaWmlEPTB;NEm0MlU6KG6P	NVvidYFKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
H9	NF\BZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknlTWM2OD12OUWuOFMhdk1?	M3jaZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
RS4-11	M3W2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;jRYJKSzVyPUWwOE44OyCwTR?=	NFiwOow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
PA-1	NFvaRlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLrZ5dKSzVyPUWwPU45PiCwTR?=	NYXhSWR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MV-4-11	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PHNWlEPTB;NUGzMlg2KG6P	NEG1PYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
OS-RC-2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHkTWM2OD13MkGuOlIhdk1?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
RPMI-8226	M3[4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTV{Nj64OkBvVQ>?	NGS4Onc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HGC-27	Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTV4ND65PUBvVQ>?	NF7nN2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
CHP-212	NEDUNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHyzPXNKSzVyPUW5N{42QSCwTR?=	NXPuUmo{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NB10	MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTV7OT6xPEBvVQ>?	NIHXVnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HH	NWj1PHlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTV7OT60N{BvVQ>?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
EW-16	NGfQVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTZyMz61NkBvVQ>?	Mk\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
ES8	MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zJRWlEPTB;NkC1MlIyKG6P	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HAL-01	MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HUS2lEPTB;NkC1MlY4KG6P	NH:z[Go9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
A204	NVzRWmlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHe1OlJKSzVyPU[zN{46OSCwTR?=	NVrId5pqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MHH-PREB-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF71cldKSzVyPU[zOk46QSCwTR?=	NEC0NGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
EM-2	NFT4Z\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPNPZR4UUN3ME22OVAvPjRibl2=	NYXvNI9ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
BV-173	MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\yb\|BKSzVyPU[1Nk41QCCwTR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
ONS-76	MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3u0ZWlEPTB;Nke3MlgzKG6P	NETtWYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
KM-H2	MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETSe45KSzVyPU[5OU42PCCwTR?=	NGfDOpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
D-263MG	M165Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXKbFdKSzVyPUexO{4yOiCwTR?=	NWnXfJpRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
ES3	NHXHO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvFRotKSzVyPUeyPE46OyCwTR?=	MlHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
VA-ES-BJ	NFXHO2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXGTWM2OD15M{KuNlchdk1?	MlnOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NBsusSR	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTd2Mj65PUBvVQ>?	M1LqdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H520	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzFW3dKSzVyPUe0Ok42OiCwTR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
ES5	MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTd3Mj64JI5O	NHf6dXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
T-24	NFzrZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXsd4NGUUN3ME23O\|gvPzFibl2=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SW962	M4iw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRThyOD62N{BvVQ>?	Mnj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
EW-3	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4n6WWlEPTB;OEC4Mlc3KG6P	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
RXF393	NGPqenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HvUmlEPTB;OEGyMlc6KG6P	M3foSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
U251	NET6SJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HyZmlEPTB;OEGzMlg5KG6P	M2\IN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
CAMA-1	NYfUR3B5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TWU2lEPTB;OEOzMlk1KG6P	NWDuVI51RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
JVM-3	NXXuVXlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DQXGlEPTB;OEWxMlc5KG6P	NUe1XnFYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
COLO-800	M{XQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTh7Nz63PEBvVQ>?	MoPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
OVCAR-5	NUP6bnRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPJTXdKSzVyPUmwNE4yKG6P	NWTaUpYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
LB1047-RCC	NYrxR4ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITOb4dKSzVyPUmyO{42PiCwTR?=	Mn3YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
SW954	M2HOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvVWGZKSzVyPUmyPU41OSCwTR?=	M1v5ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
J-RT3-T3-5	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTNZlZvUUN3ME25N\|YvODZibl2=	MmLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
Mewo	NUG1boFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDnTWM2OD17M{[uOkBvVQ>?	NIfWWYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H1770	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIO4c5NKSzVyPUm0NE42PSCwTR?=	NHzDTXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HO-1-N-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTl4Mj64NUBvVQ>?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HSC-3	NV75PXlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHDVWpKSzVyPUm2Ok41QCCwTR?=	M3LtNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
TYK-nu	NVjxfm9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;ad2lKSzVyPUm5PE4zPSCwTR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
KYSE-150	M2PkU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTFwMECwO\|Yh\|ryP	NX;HTIxxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SN12C	NF2xNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2P6eGlEPTB;MT6wNFg4PSEQvF2=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
MOLT-13	MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrzenFKSzVyPUGuNFE1OjFizszN	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
TE-11	M{HEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTFwMES4NVIh\|ryP	MlzlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
DB	NGnkN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NISzTHBKSzVyPUGuNFczPzNizszN	NF7HdW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
CAL-39	NF7WTGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlv1TWM2OD1zLkC3OVIzKM7:TR?=	Ml\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
A3-KAW	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXQOZdKSzVyPUGuNFg1ODhizszN	M4K3RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
CHP-134	MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLHTWM2OD1zLkGxPFA4KM7:TR?=	M1\peFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
TGW	NFznNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTFwMUKzPVUh\|ryP	MnmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkWyTWM2OD1zLkGzNVM1KM7:TR?=	MlHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-SNU-1	NILHU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoG3TWM2OD1zLkG2N\|U1KM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
CGTH-W-1	NVzTT4I4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTFwMUexPFYh\|ryP	NWTRc5p4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MHH-ES-1	M{PRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTFwMUe5PFYh\|ryP	NWHieIduRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
LB2241-RCC	NEHYbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2r1eWlEPTB;MT6xPFYzKM7:TR?=	M2LENVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
ML-2	MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\YTWM2OD1zLkKwO\|M1KM7:TR?=	NUnUd4hNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
COR-L23	M2LM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;vdWlEPTB;MT6yNlk{OyEQvF2=	M1vJOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
BFTC-905	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLkTWM2OD1zLkK0NlY4KM7:TR?=	MkXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
Hs-578-T	NWTBbYd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTFwMkW4NVch\|ryP	MoTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
KG-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PwVmlEPTB;MT6yOlY5PiEQvF2=	NGDjNZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HEL	NGqzbllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nWfGlEPTB;MT6yPVM{QCEQvF2=	Mor5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
A549	MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjzVGpnUUN3ME2xMlI6Ozl7IN88US=>	M2faeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
COLO-741	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjlNFZKSzVyPUGuN\|IxQDlizszN	MknMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
PC-3	M2P0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTFwM{WyNlEh\|ryP	M335e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HOS	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfoTWM2OD1zLkO1Nlk3KM7:TR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HT-1080	NVX3c20yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHrb4dMUUN3ME2xMlM4PTF7IN88US=>	M4nRNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
TE-8	MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnON\|dFUUN3ME2xMlQyPzd2IN88US=>	NVTTRZR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
BHY	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1y0eGlEPTB;MT60OlkzOyEQvF2=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
BB65-RCC	M2nUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTFwNUC1Nlgh\|ryP	NF3ZR3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HN	NGXscYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGK0T3ZKSzVyPUGuOVQxPzFizszN	NG\JcVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H441	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTFwNUS5NFch\|ryP	MoPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
RPMI-8866	NVXt[YdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3KTWM2OD1zLkW4OVA4KM7:TR?=	NI\rUlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
CAL-62	Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfucJNrUUN3ME2xMlYxQDZ{IN88US=>	NIfRPGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
MG-63	Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTFwNkG4NVMh\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SK-LU-1	NEDFdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LFdmlEPTB;MT62NlE2OiEQvF2=	NVvOW2hpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
BCPAP	NF3tNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;HNoRKSzVyPUGuOlY1PTdizszN	NFrMNYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
22RV1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHKZZpKSzVyPUGuOlc5PDNizszN	NW\ZSZp3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
T47D	NIHpS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXHTWM2OD1zLk[4NFYyKM7:TR?=	NWLZe3hWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MSTO-211H	NHLvVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTFwNkm2NFMh\|ryP	MmK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
DEL	M33lVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTFwN{CyO\|Mh\|ryP	NFnXNJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
H4	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLvTWM2OD1zLkezNlEzKM7:TR?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
CAL-51	M2LK[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPzSZhvUUN3ME2xMlc1QDV3IN88US=>	NYrIOXRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
ABC-1	MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHzWIdOUUN3ME2xMlc5PTh{IN88US=>	NWnwUWNFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MZ2-MEL	MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTFwN{m1OFIh\|ryP	MmPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
YKG-1	NVzQWVRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3G2fGlEPTB;MT64NVA3OSEQvF2=	M2\ETVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
KM12	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1:0WGlEPTB;MT64NVYxOiEQvF2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
L-363	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfmNHd7UUN3ME2xMlg4PDF{IN88US=>	NVLlbHc1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KU812	M{DEbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrTeW1KSzVyPUGuPFkzQDJizszN	NIfud\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
LOXIMVI	NIiyTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1G5[2lEPTB;MT65NVIzQCEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
G-401	M4jCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PYXWlEPTB;MT65NlQzQCEQvF2=	NEHCWm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SW780	NUXINJdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTFwOU[yOFYh\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SW872	NFvVNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XwfmlEPTB;MT65PFM{KM7:TR?=	NUnydG9QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NB7	NHzLbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXYTWM2OD1zLkm5N\|I{KM7:TR?=	MmjpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
T98G	NF\oenJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LpdGlEPTB;Mj6wNFY3PiEQvF2=	NEjzfng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SW1710	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfETWM2OD1{LkC2PVQ2KM7:TR?=	MonzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1573	NXz5PIFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzhTWM2OD1{LkC3Nlk5KM7:TR?=	M3TOPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
KE-37	NVLzPWVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTsTWM2OD1{LkC4PVUyKM7:TR?=	NHTlZ4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
786-0	NF7ERXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljoTWM2OD1{LkG1OFM6KM7:TR?=	MmfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
SAS	NGXZNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3O1W2lEPTB;Mj6yNFM4PCEQvF2=	MnXjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
CAL-54	NYXPR5d7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DjZ2lEPTB;Mj6yNFQyOyEQvF2=	NUPwUHB6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SF268	M2i4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;mTWM2OD1{LkKzNVIzKM7:TR?=	Mm\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
SW620	NHPhcVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWC0WVFIUUN3ME2yMlI3OTZ7IN88US=>	NWPOdYxqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MN-60	MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPr[3I4UUN3ME2yMlMyODZizszN	MniyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
EFO-27	MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTJwM{KwOVgh\|ryP	MnHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H747	MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIH6W5ZKSzVyPUKuN\|IyQTlizszN	NYe4R291RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HCC2218	MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF2xfWlKSzVyPUKuN\|U{PzRizszN	NIDGWJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
MIA-PaCa-2	M1XwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvqWlRwUUN3ME2yMlM3PDN5IN88US=>	M1XBS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SJSA-1	NH3sT\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7FbFRKSzVyPUKuN\|c4QTZizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
RKO	NEfKO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfzTWM2OD1{LkO4OFk3KM7:TR?=	M{X3V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NB6	NILESmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTJwNECzO\|Qh\|ryP	NIjnUW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
ES4	M2TRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDmUJNPUUN3ME2yMlQ2PDJ{IN88US=>	MkK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
EGI-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTJwNE[4PFMh\|ryP	Mn;aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
CTV-1	NX7uSVlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTJwNUK3O\|Mh\|ryP	NHK5bFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H1355	M{fIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTJwNUW5OVEh\|ryP	NIDtcIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
GT3TKB	M1TGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUD0V4pQUUN3ME2yMlU6OTl7IN88US=>	M2LOVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SK-HEP-1	M37Be2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rueWlEPTB;Mj61PVI3PiEQvF2=	NEPqbYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
GAMG	NGrqXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTyTWM2OD1{LkW5N\|k1KM7:TR?=	M33IbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SK-MES-1	Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjIcmJrUUN3ME2yMlYyQDB\|IN88US=>	M{fJNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
RO82-W-1	MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2i3XmlEPTB;Mj62NlA2PyEQvF2=	M1vENVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
ECC10	M1HWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTJwN{CyNFYh\|ryP	M{O2[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MCF7	NV;JflBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG[4ZmhKSzVyPUKuO\|E1PjRizszN	MkmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
D-283MED	NYW3T\|NsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjzSoZXUUN3ME2yMlczPDNizszN	MnO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
RPMI-7951	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3S4NmlEPTB;Mj63OVY6PCEQvF2=	M1n1SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1z2bmlEPTB;Mj63O\|A6QSEQvF2=	NHm5[ZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
KGN	NUTVXYdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\YTWM2OD1{LkixPFg1KM7:TR?=	NWjCcJJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NUGC-3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTJwOEK1NFUh\|ryP	M3O0VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H292	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTJwOEWwOVMh\|ryP	NWfjTJNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
Becker	M2HB[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4qzVmlEPTB;Mj65OVg{OiEQvF2=	MlviQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1299	MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjqT4tiUUN3ME2zMlA2OjZ\|IN88US=>	NWHzd\|hZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
ETK-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TYPGlEPTB;Mz6wOVQ{KM7:TR?=	NH3yVlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
TK10	MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrQTWM2OD1\|LkKwNVY2KM7:TR?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
VMRC-RCZ	M3PlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTNwM{[0PFgh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
YH-13	NV33cId1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXQTZBpUUN3ME2zMlQ1ODd7IN88US=>	M{HFXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
DU-145	NXzjNZJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTNwNE[yOlkh\|ryP	NVHV[lczRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SW1088	NHfrUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHyTWM2OD1\|LkS3OFch\|ryP	M2nZWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HOP-92	MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7mTGRKSzVyPUOuOVA{PDJizszN	NFvCWWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
KP-N-YS	M2Dzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTNwNkKxN\|kh\|ryP	MlviQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H460	MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTNwNk[3N{DPxE1?	NX;OVW1kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
U-2-OS	M3:wXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnT2TWM2OD1\|LkeyOVM2KM7:TR?=	NUP6bINLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
A101D	NFPGPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjpRm9KSzVyPUOuO\|Y6OzZizszN	M{XDb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MDA-MB-231	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHL5b4RKSzVyPUOuPFE6PTFizszN	NWrwbFlyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
IST-MES1	NHjT[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfNW2ZKSzVyPUOuPFMzKM7:TR?=	MkfPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
COR-L105	NXHBNFdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTRwMEG4JO69VQ>?	Mk\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1437	MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NET1S5dKSzVyPUSuNFI{ODJizszN	M{e1VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
CAL-85-1	M2C2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTRwMEK0OlEh\|ryP	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
MZ1-PC	Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTRwMUi1OVYh\|ryP	M4fWS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
VM-CUB-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PQWGlEPTB;ND6zNVI5PCEQvF2=	MkTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
CHL-1	NFLBOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2SxeWlEPTB;ND6zNlE3QSEQvF2=	NVfuTpBXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MDA-MB-361	NF;HT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml75TWM2OD12LkOzNVU{KM7:TR?=	M1\oXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H661	M1f4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTRwNUCwPVIh\|ryP	M{nMVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
EW-11	M3\OZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDXbnV{UUN3ME20MlUzOjNzIN88US=>	MmHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
BEN	NH60fFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vEdGlEPTB;ND61NlgyPSEQvF2=	NWnKOYtvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
BFTC-909	NYPKelZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTRwNU[yO\|Uh\|ryP	M3rsbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H2087	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjvTWM2OD12LkW4NVY1KM7:TR?=	M1n5TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
RVH-421	MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXhfZZKSzVyPUSuOlY3QSEQvF2=	NYPPTWZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
P30-OHK	M1;U[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPpeoFoUUN3ME20MlY5ODB6IN88US=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H28	M4HJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTRwOEG2OlEh\|ryP	M3e1NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
ES6	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUW2XmVkUUN3ME20Mlg{ODF4IN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
769-P	MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\I[GkzUUN3ME20Mlg2QTJ4IN88US=>	NVP4UpIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
OE33	MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTRwOEixOlEh\|ryP	M4ezTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SW982	NFLqbmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moq1TWM2OD12Lkm1NFYyKM7:TR?=	MmK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
A388	NGXSSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvHPGtKSzVyPUWuNFI6QDNizszN	M4\4TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
TI-73	NGLY[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfSTWM2OD13LkC2NVk1KM7:TR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HCT-116	MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M122OmlEPTB;NT6wPVg5QSEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HuP-T3	M3HTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmr2TWM2OD13LkG4O\|A6KM7:TR?=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
G-402	NF:zfYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;nXm03UUN3ME21MlE6PDF4IN88US=>	M4C1SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H1792	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrWfXdKSzVyPUWuNlQ3OjJizszN	MoD4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H209	NIq2U49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTVwMkW5OFIh\|ryP	Mo\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1650	MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXW2THloUUN3ME21MlMxPjN2IN88US=>	M3nUZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
LCLC-97TM1	M1TIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTVwM{G4NFgh\|ryP	NHnpbHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
S-117	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLxNmpuUUN3ME21MlM3QTd4IN88US=>	M4S1Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
GI-ME-N	NWSyTJNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTVwM{m2PFEh\|ryP	M13FeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H2122	M2PIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELzNYxKSzVyPUWuOFk{QTdizszN	M{HRZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H1793	NU[zb5prT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTYWm9LUUN3ME21MlY4PTl\|IN88US=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
C2BBe1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTVwN{CwPFgh\|ryP	NWLZSnlYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
TE-12	MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPTTWM2OD13LkiwOVU3KM7:TR?=	MlqxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
LCLC-103H	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HxR2lEPTB;NT65NVch\|ryP	NEiyOXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
A673	M2W5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{W0UmlEPTB;NT65NVk{OiEQvF2=	NWryNlc1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
BB30-HNC	M2X1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTVwOUizOkDPxE1?	M1v0W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SF295	NYLBNohMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfwTYhmUUN3ME22MlAxPDJ{IN88US=>	M2TiSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
KU-19-19	MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2GzNGlEPTB;Nj6wNVc{OSEQvF2=	MnK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
CFPAC-1	NW\obFVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;pTWM2OD14LkC0OFQ{KM7:TR?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
LoVo	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTZwMEWwOlMh\|ryP	NWK5ZY5LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
8505C	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTZwMEe1O\|Mh\|ryP	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
GMS-10	NEXJTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DYPWlEPTB;Nj6xOVAxOiEQvF2=	Ml7DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
Ca9-22	NFPoSnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTZwMU[3NUDPxE1?	NWT5TIhJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
DOK	M4XR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGr5WGRKSzVyPU[uNlIxPzJizszN	NWewS4Z7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
FADU	Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XCPWlEPTB;Nj6yOlA{QSEQvF2=	MmXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
BxPC-3	NY\VSIdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTZwMkezNkDPxE1?	NWi1R2VkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
CAL-33	NXzFdYpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HoSGlEPTB;Nj6yPVIxOSEQvF2=	NXHrdG04RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SHP-77	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HPPGlEPTB;Nj6zNVUyOiEQvF2=	NFjROFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
LXF-289	MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjGTWM2OD14LkOzOFU2KM7:TR?=	MlfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
GB-1	MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jmOGlEPTB;Nj6zPFIh\|ryP	M1yxUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
KS-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTZwM{i0OFch\|ryP	NHXDTJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
D-502MG	MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;PWmlEPTB;Nj60NlM4PiEQvF2=	NUHqPGtIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
LAN-6	NI\HdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTZwNUGwNlMh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
H-EMC-SS	NV3PVXpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrDZ5dmUUN3ME22MlU3OTR5IN88US=>	Mmj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
LC-2-ad	NUP5ZW16T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnoT3NrUUN3ME22MlYxODd4IN88US=>	NIrFeFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H1693	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTZwNkKyNVUh\|ryP	NEL2XmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SK-N-FI	M2S3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTZwN{WwOFQh\|ryP	M{\KVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
D-423MG	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHVUHVKSzVyPU[uO\|YyOTdizszN	MkjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
KNS-42	NV\Wd\|ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HIUmlEPTB;Nj63PFE6PyEQvF2=	NXnVW2xbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
GCT	NV;RfFZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fifmlEPTB;Nj65N\|gh\|ryP	NFLvPW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
DSH1	NYLMZ5Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvabFFKSzVyPUeuNFY{OyEQvF2=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
D-247MG	NGH0SIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DWOGlEPTB;Nz6wO\|g5OSEQvF2=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-SNU-5	NGXSZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTdwMUizO\|Eh\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
TE-6	NWDDXm5ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XUNWlEPTB;Nz6yNFYxOSEQvF2=	NF3mTGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NOMO-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rOSGlEPTB;Nz6yNlEzPyEQvF2=	M1rrPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NB17	MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHuUoVKSzVyPUeuN\|A{ODlizszN	Ml\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
EW-22	M3O0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDyTWM2OD15LkO0N\|Q5KM7:TR?=	M3rZdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
EW-13	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPyRlI{UUN3ME23MlM2OTZ{IN88US=>	Mlv5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
DOHH-2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mln6TWM2OD15LkS0NFIh\|ryP	NHjmTWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
TGBC1TKB	NGjhfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPxfIVKSzVyPUeuOFk5QTlizszN	NUfMUZlmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
GR-ST	M13SXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml65TWM2OD15LkWyOVk1KM7:TR?=	NGi0[4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
KYSE-520	NYeyWplVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkWxTWM2OD15LkW1OVE2KM7:TR?=	NYTnb5M2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
CAPAN-1	NH7jW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vmV2lEPTB;Nz61PVUyKM7:TR?=	M1jMTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HCE-4	MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTdwNkKyO\|kh\|ryP	MnjqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
MLMA	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3oTWM2OD15Lk[yPVU4KM7:TR?=	M2nsZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HT-144	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEG3b3VKSzVyPUeuOlU{PjhizszN	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
KYSE-180	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTdwN{GxOlkh\|ryP	M4DiTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
TE-5	NVj1eIp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDTTWM2OD15Lkm1PVcyKM7:TR?=	M3XBOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
IGROV-1	MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTdwOUi1OVEh\|ryP	NV7HRVN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H1581	NH3qTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fLOWlEPTB;OD6wNVIh\|ryP	NUPJVVN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SW1990	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHBTVVKSzVyPUiuNFQ3PTlizszN	NXOyVZFqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
EFM-19	NETtRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHmxbXNKSzVyPUiuNFg2PDVizszN	M{GzZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
OGR-1	NVXCeY8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXj5PVlQUUN3ME24MlQ{ODJ\|IN88US=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
U-118-MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnrTWM2OD16LkSzOFY{KM7:TR?=	NFvlS4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SK-OV-3	M{X3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTsTWM2OD16LkS2O\|Y2KM7:TR?=	NX7XfXB[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KNS-62	MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlSwTWM2OD16LkWxO\|YyKM7:TR?=	NFLFWJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
GOTO	NV3KU\|FlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLOTWM2OD16LkW3OlM2KM7:TR?=	M3TjWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
8305C	NHzxOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRThwN{C0PFQh\|ryP	M4nGUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
RPMI-2650	NHnSNI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;mcGlEPTB;OD63NVk2PSEQvF2=	MkP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NEC8	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;JZ5pNUUN3ME24Mlc1OzB5IN88US=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
KYSE-450	MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlraTWM2OD16Lki2OVQ5KM7:TR?=	MmG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
RMG-I	M{[zS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTWRXN2UUN3ME25MlE1ODV6IN88US=>	M1\UflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
CAKI-1	NYHVSFJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHFbJJKSzVyPUmuN\|E6PzlizszN	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
KYSE-510	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnGTWM2OD17LkO1O\|c5KM7:TR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
A4-Fuk	MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTlwM{[3NFEh\|ryP	NU\3b2RJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
AN3-CA	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTlwNEW0OFQh\|ryP	M3XFSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SK-N-DZ	NVLDSYw5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoqzTWM2OD17LkeyPFQ6KM7:TR?=	M3L3V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HSC-2	M1Xhe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlP3TWM2OD17Lke2OlI6KM7:TR?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
EW-1	NX3HOY41T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU[zPVQzUUN3ME25Mlc6OzZ7IN88US=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
D-566MG	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUe4doJlUUN3ME25Mlg{PjZ2IN88US=>	NHnJfXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
COLO-792	M{PW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnHOWNKSzVyPUmuPVg4PDZizszN	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
TE-10	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYC0T2FxUUN3ME2xNE4xOzl4IN88US=>	NUPBdHNKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H650	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7UTWM2OD1zMD60Nlg3KM7:TR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
U-266	MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrNcGRoUUN3ME2xNE41PTVizszN	MmS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
Detroit562	M3P1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoToTWM2OD1zMT6wOVE2KM7:TR?=	M4PCflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NH-12	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\CTWM2OD1zMT6xOFQ3KM7:TR?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
CO-314	NV\EbWpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LWWGlEPTB;MUGuNlg1OiEQvF2=	NYjuSWpvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
IST-MEL1	M2DqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHvTWM2OD1zMT61N\|I{KM7:TR?=	NF;FcY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
KNS-81-FD	Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nlVWlEPTB;MUGuOVUzPyEQvF2=	NXf5U2QyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SW1463	NH7SO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXj1ZWo{UUN3ME2xNU42QTh7IN88US=>	NXX3[m15RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H23	M3v6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPRVpZvUUN3ME2xNU43PTV{IN88US=>	NV;kToRTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SK-MEL-2	NUfrZlRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXr0cWp3UUN3ME2xNU44OTl5IN88US=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NB13	MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HRWWlEPTB;MUKuNVQ6PSEQvF2=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
Daoy	M3fYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILwbWRKSzVyPUGyMlI5PTZizszN	NVL2SYZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H1623	NIHkc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTF{LkO4NFEh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NMC-G1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlW3TWM2OD1zMj63NVch\|ryP	NGm2Vow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
DK-MG	NIT1T4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPo[VFKSzVyPUGyMlk1QDJizszN	NVjW[mM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
TCCSUP	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvTTWM2OD1zMz6xNlg1KM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SCC-15	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlL0TWM2OD1zMz6yOlUyKM7:TR?=	NXnEdHdiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NOS-1	MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LNVmlEPTB;MUOuNlg6OyEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
RH-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjofJI6UUN3ME2xN{4{ODN5IN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SK-MEL-3	NGf0PY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfYTWM2OD1zMz6zO\|I5KM7:TR?=	NWrlW4YzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NB5	Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\vPZFxUUN3ME2xN{41ODZ5IN88US=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SNU-387	NFjGUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTF\|LkWwO\|Ih\|ryP	MkTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
CAL-120	MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DjNmlEPTB;MUOuOlcyQCEQvF2=	M1e2PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
Mo-T	NITld\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoW1TWM2OD1zMz63NFch\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
LNCaP-Clone-FGC	MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXz2RVcyUUN3ME2xN{44QTl{IN88US=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
CAN	NWXwfYpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTF2LkCyPFgh\|ryP	M1THTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SK-MEL-30	M2PYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrqb2RnUUN3ME2xOE4xPjNizszN	NYe4OlRJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
COLO-678	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTF2LkC4NlIh\|ryP	NGTqcmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SCC-9	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTF2LkGwNlEh\|ryP	NGnTUGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
KINGS-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnq5TWM2OD1zND6xOFAzKM7:TR?=	NX72SnlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SL-513	NFLGXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTF2LkG4O{DPxE1?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HLE	M4HFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TDd2lEPTB;MUSuN\|g2OiEQvF2=	NWLTVHhrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SW1573	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV:3[YVTUUN3ME2xOE41PDN3IN88US=>	NWLX[YVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KYSE-140	M2jrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTF2Lk[zNlch\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SK-PN-DW	NF3aUHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzCNGFKSzVyPUG0MlgxODFizszN	NFrzXHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
A253	NIDrd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnZ[GNUUUN3ME2xOU4xPjJ3IN88US=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
CAL-12T	M3joe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTF3LkS2OlIh\|ryP	M3vWeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
COLO-679	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DDOGlEPTB;MUWuO\|Y5OyEQvF2=	NVKzZ3RLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
UACC-257	NU\NcZJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jHZmlEPTB;MU[uNVIxOSEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
U-87-MG	NIeyR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn36TWM2OD1zNj6zOVI{KM7:TR?=	NXG4cIlIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HCC1806	NGrwXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvXSFY{UUN3ME2xOk44ODdzIN88US=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H2170	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;vRmlEPTB;MUeuNlQ1QCEQvF2=	M2PDUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
AGS	NFrW[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1OyeWlEPTB;MUeuN\|gxQCEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
MEL-HO	NETtXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonjTWM2OD1zNz63OVA{KM7:TR?=	M4O5cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SW48	NWTUfpZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLTN2t6UUN3ME2xO{44PzF4IN88US=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HuP-T4	NF7xUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LE[GlEPTB;MUiuNFIxPiEQvF2=	M2LselxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H720	M4KyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfnTWM2OD1zOD6xOFAzKM7:TR?=	M3nxflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
RCC10RGB	NGTKV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfSWWdKSzVyPUG4MlE3QTdizszN	M33QW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HD-MY-Z	NFm4VpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPkPXJDUUN3ME2xPE4zOjV2IN88US=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
A427	M1XvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTF6LkWwPVQh\|ryP	Mm\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
HCC2998	NFn0T2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrWTWM2OD1zOD62NFUyKM7:TR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
EPLC-272H	NFq3Z5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzEXmVsUUN3ME2xPU4xPDN2IN88US=>	NI\aPZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
C32	M{\y[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILQPZFKSzVyPUG5MlA1PSEQvF2=	M2jKR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
UMC-11	MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDMU\|hNUUN3ME2xPU4zOTJ\|IN88US=>	NGrBN4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
CaR-1	NIjPcYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTF7Lk[4NFQh\|ryP	NGXMVZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
KYSE-410	Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLTSYlpUUN3ME2xPU46OTN7IN88US=>	M3vDOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HuCCT1	M4fDW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrHOZdKUUN3ME2yNE43Ojl2IN88US=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
LB996-RCC	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfTcVZ3UUN3ME2yNE44OTZ6IN88US=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
KYSE-70	Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojiTWM2OD1{MD64NFU6KM7:TR?=	M4jNWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
CAL-72	NWniZZRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvabIZKSzVyPUKwMlkyPSEQvF2=	NI\WOJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
Capan-2	M1LEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\2TWM2OD1{MT6wOFE{KM7:TR?=	NUTpSpFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
PANC-08-13	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPhTWM2OD1{MT6yOVE2KM7:TR?=	NHn3dm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SBC-1	NGXEVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTJzLkOwPFEh\|ryP	M2HLPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MFM-223	NVvU[VdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTJzLkOzOFIh\|ryP	NIHYNVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
BB49-HNC	MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfhfoNnUUN3ME2yNU42PzF4IN88US=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SH-4	M1\IVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3CTWM2OD1{MT62OlE5KM7:TR?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HuO9	M1;NXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTJzLkm4NlUh\|ryP	M{\ZdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
AM-38	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXufG9KSzVyPUKyMlA1QDVizszN	NV\DSlJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
A431	NVnlOpBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\HTWM2OD1{Mz6yNVE6KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
YAPC	Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTJ\|LkK2OVEh\|ryP	Mo\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
LU-139	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTJ\|LkS4NFkh\|ryP	NFfnRXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HEC-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTJ\|LkS5N\|ch\|ryP	M1y0R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SCC-25	M2HnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH33foFKSzVyPUK0MlMxODZizszN	NHXwdoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HT-29	M3vDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\qTWM2OD1{ND6zPFI{KM7:TR?=	MnvOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
PC-14	NXX6dFhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\zNGlEPTB;MkSuOlU4OSEQvF2=	M2LlPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
Calu-6	M2qyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4Lt[mlEPTB;MkWuOVA4OSEQvF2=	NFS0[G89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SJRH30	NHHwUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTkTWM2OD1{NT62OFk3KM7:TR?=	MoP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
ChaGo-K-1	NG\wcHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTJ4LkG2Nlkh\|ryP	M4\Pe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
IA-LM	M3G1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTJ4LkO2OFUh\|ryP	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
GP5d	M2fpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTJ4LkS0PVEh\|ryP	MmLsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H2291	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3uVmw6UUN3ME2yOk43PTRzIN88US=>	MlThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
BALL-1	NXrlfW93T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Lx[2lEPTB;Mk[uPVM6PyEQvF2=	NHHCUok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HCC1954	NWTKd4hPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjwXXJIUUN3ME2yOk46QDB6IN88US=>	NWnXepBFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H2452	NGK2SXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTvTWM2OD1{Nz60NVY{KM7:TR?=	MnHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
LU-99A	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3mwSWlEPTB;MkeuOVU5OiEQvF2=	M{D0OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NTERA-S-cl-D1	MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXKTnNGUUN3ME2yO{44Ojl7IN88US=>	MmnJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
PANC-10-05	NInZfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnDOXFKSzVyPUK3Mlc4PzVizszN	NGLvZ2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H2405	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFziUW1KSzVyPUK3Mlk{QDdizszN	NUfVZ\|hLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MDA-MB-415	NFTMfGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;sTWM2OD1{OD60NVM4KM7:TR?=	NVizZ4JPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H2342	M2D3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHL1WGZKSzVyPUK4MlUzQDFizszN	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
TGBC24TKB	NVHuWJJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rCXWlEPTB;MkiuO\|EyPyEQvF2=	NYfGNnFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
LU-134-A	NEflbXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTRTWM2OD1{OD65NlYyKM7:TR?=	M4rFVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SCC-4	NY[ze4hLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXyc25KSzVyPUOxMlA1QTRizszN	NHzhUXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
Saos-2	NX65TW05T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTNzLkmzNFYh\|ryP	NX3pUYx3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
RERF-LC-MS	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPFTWM2OD1\|Mj64NlMyKM7:TR?=	NXiwcYEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
M14	NVvNc5FUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPrTWM2OD1\|Mj65O\|Y1KM7:TR?=	MmGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
HPAF-II	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PPbWlEPTB;M{OuOVAyOSEQvF2=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H1755	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTN2LkOzNFUh\|ryP	M2\nVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
D-392MG	NXjuUIQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;XVWlEPTB;M{WuPFY4PCEQvF2=	NF\ncVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
A704	NVXE[Fl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTN4LkC0Nlch\|ryP	NWPNXmUzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
CP50-MEL-B	NHzETGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vTRWlEPTB;M{[uNVkyOSEQvF2=	NYnuW2RORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
EW-18	NFLUbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3lUWZ[UUN3ME2zOk41PTJizszN	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
WM-115	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXCTWM2OD1\|Nj64NFk6KM7:TR?=	NIjYelQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
LU-65	NUHq[otJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjYTWM2OD1\|Nz6xOFE4KM7:TR?=	NY\6SJBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H1563	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfnfFF1UUN3ME2zO{4zPDh2IN88US=>	Mmj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
DBTRG-05MG	NV65fmNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;ZSo9KSzVyPUO4MlA3QTFizszN	NYD1ZWRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H630	M{D6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTiTWM2OD1\|OD60O\|E1KM7:TR?=	M1jyPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H1155	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjVVpByUUN3ME2zPU4zPDJizszN	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
OVACR-3	NIP2[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXj0SZlMUUN3ME2zPU46OTl3IN88US=>	M{XEflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
OAW-42	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vGOmlEPTB;NECuOFI2QCEQvF2=	Mo\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
JVM-2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3THRWlEPTB;NEGuNlQyPSEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
C3A	NVzWNVJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4G4fGlEPTB;NEGuN\|Q1PyEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HT55	M1XWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjYWW41UUN3ME20Nk4zQDRzIN88US=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
OVCAR-4	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTR{LkK5O\|Qh\|ryP	NWL1cJV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MEG-01	M3jGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPVTWM2OD12Mj60OlE3KM7:TR?=	M4PwWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H82	MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTR\|Lkm4PVIh\|ryP	Mn7xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
JEG-3	NE\zXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37rTGlEPTB;NESuPVQ4KM7:TR?=	NXLZe\|dZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
BPH-1	NECzRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\0PJdKSzVyPUS2MlM6QThizszN	NFT6WlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
MPP-89	NImyVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfEc5lpUUN3ME20O{4zQDl6IN88US=>	NGHt[3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
ALL-PO	NV\DUIY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoP2TWM2OD12Nz60NVg5KM7:TR?=	NWXM[\|BTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HT	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTR5LkS5NkDPxE1?	NGWwdVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H2347	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HDe2lEPTB;NEiuNFcyPSEQvF2=	MmfBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
A2780	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLaTWM2OD12OT60NlI5KM7:TR?=	NX7HbIpnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KARPAS-299	MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofETWM2OD12OT61NVE6KM7:TR?=	Mm\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1651	M2rRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTR7Lki4NlEh\|ryP	NUfPeXpJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	RB1 (pT821) / RB1 (pS780) / RB1 / CDK6 / CCND2 / RUNX1 / ETO; PubMed: 30300583 Cancer Cell Immunoblots showing dose-dependent impact of 72 hr palbociclib treatment on indicated protein levels in Kasumi-1 and SKNO-1 cells. pRb(S807, 811) / CDK4 / CDK6 / PARP; PubMed: 28453226 Mol Oncol Effects of palbociclib on CDK4/6-Rb pathway. HCC cells were treated with different doses of palbociclib for 24 h, and then, the cells were subjected to western blot analysis. CF, cleaved fragment. LC3-I / LC3-II; PubMed: 28453226 Mol Oncol Palbociclib increases LC3-II amount in a dose-dependent manner in HCC cell lines. pAMPKα(T172) / pULK1(S317); PubMed: 28453226 Mol Oncol Dose-dependent response of palbociclib on AMPK-related molecules. HCC cells were treated with different concentrations of palbociclib for 24 h. The phosphorylation of the indicated proteins was determined by western blotting. SMAD2 (pS255); PubMed: 30343527 Cancer Sci T47D cells were treated with indicated concentrations of palbociclib for 24 h to evaluate substrate phosphorylation.	30300583 28453226 30343527
Growth inhibition assay	Cell viability; PubMed: 29670090 Cell Death Dis Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and 6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis.	29670090
Immunofluorescence	SAHF/ATRX; PubMed: 26988987 Cancer Res DAPI staining for senescence-associated heterochromatic foci (SAHF, left panel) and ATRX staining (right panel) in 1205Lu cells +/− palbociclib for 8 days. LC3B; PubMed: 28453226 Mol Oncol LC3B immunofluorescence in palbociclib‐treated Hep3B cells. Arrowheads indicate LC3-positive autophagosomes. Nuclei were counterstained with DAPI (blue).	26988987 28453226
ELISA	PGE2; PubMed: 26540629 Oncotarget The supernatant of control and 7.5 μM palbociclib-treated cells was collected and stored at −80°C. PGE2 secretion was detected using ELISA.	26540629

In vivo

PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse Cdk Assays: A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl₂, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-³²P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-³²P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-³²P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4 °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research: ^[1]	- Collapse Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562 Concentrations: 0.01-1 μM Incubation Time: 24 hours Method: Cells are seeded at 2 × 10⁴ per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [¹⁴C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice. Dosages: 0-150 mg/kg Administration: Given by gavage (Only for Reference)

References

[4] Katsumi Y, et al. Biochem Biophys Res Commun, 2011, 413(1), 62-68.

- Collapse

Solubility (25°C)

In vitro	Water	30 mg/mL (61.98 mM)
	DMSO	3 mg/mL warmed (6.19 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Molecular Weight	483.99
Formula	C₂₄H₂₉N₇O₂.HCl
CAS No.	827022-32-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04669587	Recruiting	Drug: ZB716\|Drug: Palbociclib	Estrogen Receptor-Positive\|HER2-Negative\|Locally Advanced Breast Cancer\|Metastatic Breast Cancer	EnhancedBio USA Inc.\|Zenopharm\|EnhancedBio Inc.	July 26 2021	Phase 1\|Phase 2
NCT04841148	Recruiting	Drug: HCQ\|Drug: Avelumab\|Drug: Palbociclib	Breast Cancer	Abramson Cancer Center of the University of Pennsylvania\|Johns Hopkins University\|Translational Breast Cancer Research Consortium\|Pfizer\|Breast Cancer Research Foundation	June 1 2021	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Most Potent CDK Inhibitor

LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.
CDK Inhibitor in Clinical Trial

Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).
Newest CDK Inhibitor

NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with K_i of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively. Purvalanol A induces endoplasmic reticulum stress-mediated apoptosis and autophagy.
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965, PS-095760) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.
Flavopiridol (L86-8275) HCl

Flavopiridol HCl (L86-8275, NSC 649890, Alvocidib, HMR-1275, DSP-2033) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol HCl induces autophagy and ER stress. Flavopiridol HCl blocks HIV-1 replication. Phase 1/2.
Roscovitine (CYC202)

Roscovitine (CYC202, Seliciclib, R-roscovitine) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
Abemaciclib mesylate (LY2835219)

Abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.
SNS-032 (BMS-387032)

SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. SNS-032 (BMS-387032) induces apoptosis. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

Palbociclib (PD-0332991) HCl